Iulian Bobe

Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300

Anthracyclines have long been considered to be among the most active agents clinically available for the treatment of breast cancer despite their toxicity. To improve their pharmacological profiles, a new macromolecular prodrug, denoted NC‐6300, was synthesized. NC‐6300 comprises epirubicin covalently bound to polyethylene‐glycol polyaspartate block copolymer through an acid‐labile hydrazone bond. The conjugate forms a micellar structure spontaneously in aqueous media with a diameter of 60–70 nm. The block copolymers are partially substituted with hydrophobic benzyl groups to stabilize the micellar structure. The present study was designed to confirm that polymeric micelles incorporating epirubicin through an acid‐labile linker improve the therapeutic index and achieve a broad range of therapeutic doses. Pharmacokinetic studies in rats showed highly enhanced plasma retention of NC‐6300 compared with native epirubicin. The maximal tolerated doses in mice of NC‐6300 and native epirubicin were 25 and 9 mg/kg, respectively, when administered three times with a 4‐day interval between each dose. NC‐6300 at 15 and 20 mg/kg with the same administration schedule regressed a Hep3B human hepatic tumor with slight and transient bodyweight loss. Remarkably, NC‐6300 also inhibited growth of an MDA‐MB‐231 human breast tumor at the same dosage. In contrast, native epirubicin at 7 mg/kg administered three times with a 4‐day interval was only able to slow tumor growth. Tissue distribution studies of NC‐6300 showed efficient free epirubicin released in the tumor at 74% by area under the concentration‐time curve (AUC) evaluation, supporting the effectiveness of NC‐6300. In conclusion, NC‐6300 improved the potency of epirubicin, demonstrating the advantage of NC‐6300 attributable to the efficient drug release in the tumor. (Cancer Sci 2011; 102: 192–199)